AI-based Drug Design and Development in the Cloud

Cloud Pharmaceuticals is a clinical stage biopharmaceutical company that is a leader in the burgeoning field of Artificial Intelligence based drug development.  The company partners, designs, develops, and licenses novel drug compounds for a wide range of medical indications to the pharmaceutical, biotechnology and medical research markets.  Novel drugs are developed through vertical holdings, typically LLCs for specific therapeutic areas.  Some of Cloud's active drug development projects are a mRNA vaccine for pancreatic cancer, a novel drug with companion biomarker for the EP3 target for thrombosis, an AI-repurposed "cocktail" for hypertension, and a novel drug targeting the monoclonal antibody B6 for a wide range of Coronaviruses.

The company was founded in 2011 by Lawrence Husick and Ed Addison, and launched with a technology license from Duke University, and has since expanded through early stage funding arrangements from Microsoft, the National Science Foundation, and the University of Florida via its Gatorade royalty fund, and has established collaborations with Glaxosmithkline (“GSK”) and Fujitsu.  The company is currently accelerating drug discovery from the start to IND to 120 days.  Cloud's new accelerated approach is based on novel developments, including quantum computing technology developed with Fujitsu, an inhibitor/agonist database for the druggable genome, and a strategic partnership with Drug Logic for therapeutic/vaccine development and for the repurposing of drugs based on mining EMR.